Direct-Acting Oral Anticoagulants: A Resident-Based Workshop to Improve Knowledge and Confidence

INTRODUCTION: Direct-acting oral anticoagulant (DOAC) prescriptions have increased steadily since the first, dabigatran, was Food and Drug Administration-approved in 2010. They have multiple advantages over vitamin K antagonists including fixed dosing without coagulation lab monitoring, rapid onset...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Irsk, Arora, Vineet M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Association of American Medical Colleges 2020
Materias:
Original Publication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526504/
https://www.ncbi.nlm.nih.gov/pubmed/33015358
http://dx.doi.org/10.15766/mep_2374-8265.10981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526504/
https://www.ncbi.nlm.nih.gov/pubmed/33015358
http://dx.doi.org/10.15766/mep_2374-8265.10981

Ejemplares similares